Clinically, both tumor groups correlate with advanced stage, rapid progression, and resistance to vascular endothelial growth factor (VEGF)-targeted therapies, though immune checkpoint inhibitors show emerging benefit, especially in PD-L1-positive sarcomatoid cases. The gene discussed is VEGFA; the disease is neoplasm.